Ursodeoxycholic Acid Market Size & Growth Forecast 2027–2036, By Segments (Type, Application, Mode, Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to content
Market Size and Growth Outlook
Ursodeoxycholic Acid Market size was estimated at USD 808.68 Million in 2026 and is projected to grow at 10.5% CAGR from 2027 to 2036, attaining USD 2.19 Billion by 2036. The industry revenue for 2027 is assessed at USD 882.19 Million.
Get more details on this report
Request Free Sample ReportUrsodeoxycholic Acid Market Intelligence Snapshot
Regional Market Dynamics
- North America led in 2026 due to advanced healthcare infrastructure, established pharmaceutical distribution, and broad access to diagnostic and therapeutic services.
- Asia Pacific is the fastest-growing region, supported by improving healthcare infrastructure, rising investment, wider pharmaceutical access, and growing awareness of liver and biliary disorders.
Segment Momentum
- In-house manufacturing led the market in 2026 by enabling manufacturers to maintain production quality, process efficiency, supply reliability, and consistent pharmaceutical standards while meeting regulatory requirements.
- Contract manufacturing is growing as pharmaceutical companies increasingly outsource production to improve flexibility, expand manufacturing capacity, and optimize resources without significant infrastructure investments.
Market Expansion Drivers
- Rising prevalence of liver diseases and gallstones increasing global therapeutic demand
- Expanding pharmaceutical industry improving accessibility and distribution of hepatoprotective drugs
- Increasing R&D in hepatology enhancing formulation and efficacy of ursodeoxycholic acid treatments
Leading Market Participants
- Leading companies in the ursodeoxycholic acid market include Merck KGaA (Germany), Daewoong Bio (South Korea), Dipharma Francis S.r.l. (Italy), IOL Chemicals and Pharmaceuticals Ltd. (India), Glenmark Pharmaceuticals Ltd. (India), Axplora (France), Anant Pharmaceuticals Pvt Ltd (India), ChemChina Pharmaceutical (China), Shandong Xinhua Pharmaceutical Co., Ltd. (China), Zhongshan Belling Biotechnology Co., Ltd. (China)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 808.68 Million
- 2027 Estimated Market Size: USD 882.19 Million
- Projected Market Size: USD 2.19 Billion by 2036
- Growth Forecast: 10.5% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Synthetic Ursodeoxycholic Acid (Type) | Primary Biliary Cholangitis (PBC) (Application) | In-house Manufacturing (Mode) | Human (Use)
- Emerging Opportunity Segment: Synthetic Ursodeoxycholic Acid (Type) | Primary Biliary Cholangitis (PBC) (Application) | Contract Manufacturing (Mode) | Veterinary (Use)
Market Growth Drivers and Industry Trends
Rising prevalence of liver diseases and gallstones increasing global therapeutic demand
The growing incidence of liver disorders and gallstone-related conditions is increasing the need for effective pharmacological therapies that support long-term disease management. This trend will drive the ursodeoxycholic acid market growth as healthcare providers continue to prescribe ursodeoxycholic acid for conditions requiring improved bile flow and hepatoprotective treatment. Greater awareness of chronic liver health, earlier diagnosis, and expanding access to specialist care are also contributing to broader utilization of established therapeutic options across both hospital and outpatient settings.
Expanding pharmaceutical industry improving accessibility and distribution of hepatoprotective drugs
Ongoing expansion of pharmaceutical manufacturing and distribution networks is strengthening the availability of hepatoprotective medications across developed and emerging healthcare markets. The ursodeoxycholic acid market benefits from this development as improved supply chains, broader retail pharmacy coverage, and enhanced healthcare infrastructure increase patient access to essential liver disease treatments. Pharmaceutical companies are also extending their geographic reach through strategic distribution partnerships, enabling consistent product availability across a wider range of medical facilities and healthcare providers.
Increasing R&D in hepatology enhancing formulation and efficacy of ursodeoxycholic acid treatments
Growing investment in hepatology research is encouraging the development of improved drug formulations and treatment approaches for liver-related diseases. The ursodeoxycholic acid market is gaining momentum as research efforts focus on enhancing therapeutic effectiveness, optimizing dosage forms, and improving patient adherence through formulation innovation. Clinical and pharmaceutical advancements are also supporting a deeper understanding of disease mechanisms, allowing treatment strategies to be refined for a broader range of hepatobiliary disorders.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of liver diseases and gallstones increasing global therapeutic demand | 2.2% | High | North America, Europe, Asia Pacific | High | Near Term |
| Expanding pharmaceutical industry improving accessibility and distribution of hepatoprotective drugs | 1.9% | High | Asia Pacific, North America | High | Near Term |
| Increasing R&D in hepatology enhancing formulation and efficacy of ursodeoxycholic acid treatments | 1.6% | High | Europe, North America | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the ursodeoxycholic acid market, North America held the largest share in 2026, supported by advanced healthcare infrastructure, established pharmaceutical distribution networks, and broad access to diagnostic and therapeutic services. The region's developed healthcare systems facilitate the management of liver and biliary disorders for which ursodeoxycholic acid is used. In addition, continued healthcare expenditure and greater awareness of chronic hepatobiliary conditions contribute to sustained demand for established therapeutic options.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is anticipated to experience the fastest growth in the ursodeoxycholic acid market, reflecting improvements in healthcare infrastructure, expanding access to pharmaceutical treatments, and growing awareness of liver and biliary disorders. Increasing healthcare investment across emerging economies is strengthening the availability of diagnostic and treatment services, while improvements in pharmaceutical distribution are supporting wider access to therapies. The region's large patient population and evolving healthcare systems further provide a favorable environment for market expansion.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants/StartupsiScaleLowMedium High | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Chronic Liver CareThe U.S. ursodeoxycholic acid market supports ongoing treatment for chronic liver disorders through established specialty prescribing channels. Companies operating in the U.S. prioritize product availability, regulatory compliance, and dependable pharmaceutical supply.
Germany 🇩🇪
Evidence-Based Therapy AdoptionGermany emphasizes ursodeoxycholic acid use within established clinical treatment guidelines for liver disease management. Suppliers serving Germany focus on consistent manufacturing quality, reliable distribution, and alignment with healthcare reimbursement expectations.
Japan 🇯🇵
Long-Term Treatment ReliabilityJapan values stable access to ursodeoxycholic acid for long-term management of hepatobiliary conditions within routine clinical practice. Manufacturers in Japan emphasize product consistency, quality assurance, and sustained healthcare provider engagement.
South Korea 🇰🇷
Expanding Hepatology ServicesSouth Korea supports the ursodeoxycholic acid market through expanding specialist care for liver-related conditions and structured hospital procurement. Suppliers strengthen their position in South Korea with reliable supply continuity and regulatory compliance.
France 🇫🇷
Guideline-Aligned PrescribingFrance maintains demand for ursodeoxycholic acid through clinically guided treatment approaches for chronic liver diseases. Companies serving France prioritize dependable product supply, pharmaceutical quality, and support for established prescribing practices.
Italy 🇮🇹
Hospital Treatment ContinuityItaly relies on consistent ursodeoxycholic acid availability to support hepatology care across hospital and outpatient settings. Suppliers in Italy focus on stable procurement participation, product quality, and efficient distribution to healthcare providers.
Ursodeoxycholic Acid Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: Synthetic Ursodeoxycholic Acid (Largest & Fastest-Growing Segment)
The synthetic ursodeoxycholic acid segment dominated the ursodeoxycholic acid market, accounting for 65.76% share in 2026, while also representing the fastest-growing segment within the type category. Synthetic ursodeoxycholic acid benefits from consistent production capabilities, controlled quality standards, and reliable availability for pharmaceutical applications. The ability to maintain standardized formulations and support large-scale therapeutic requirements has contributed to its widespread adoption. Increasing demand for effective treatments involving ursodeoxycholic acid has further reinforced the importance of synthetic production methods.
Application Segment Analysis: Primary Biliary Cholangitis (PBC) (Largest & Fastest-Growing Segment)
The primary biliary cholangitis (PBC) segment led the ursodeoxycholic acid market, accounting for 60.38% share in 2026, while also emerging as the fastest-growing application segment. Ursodeoxycholic acid is widely recognized for its role in managing PBC, which has supported strong demand within this therapeutic area. Growing awareness of liver-related disorders and the importance of disease management solutions have contributed to the continued expansion of this application segment. The established clinical relevance of ursodeoxycholic acid in PBC treatment continues to strengthen its market position.
Mode Segment Analysis: In-house Manufacturing (Largest Segment) vs Contract Manufacturing (Fastest-Growing Segment)
The in-house manufacturing segment maintained the leading position in the ursodeoxycholic acid market in 2026, supported by manufacturers’ focus on controlling production quality, process efficiency, and supply reliability. Internal manufacturing capabilities enable better oversight of pharmaceutical production activities and help maintain consistency in product standards. The importance of dependable supply chains and regulatory requirements has contributed to the continued preference for in-house manufacturing.
The contract manufacturing segment is gaining traction as pharmaceutical companies increasingly adopt outsourcing strategies to improve flexibility and optimize production resources. Contract manufacturers provide specialized capabilities and enable companies to expand production capacity without significant investments in internal infrastructure. The growing need for efficient manufacturing models and adaptable production solutions is supporting increased adoption of contract manufacturing.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Synthetic Ursodeoxycholic Acid, Biological Ursodeoxycholic Acid | Synthetic Ursodeoxycholic Acid | Synthetic Ursodeoxycholic Acid |
| Application | Primary Biliary Cholangitis (PBC), Gall Stones, Others | Primary Biliary Cholangitis (PBC) | Primary Biliary Cholangitis (PBC) |
| Mode | In-house Manufacturing, Contract Manufacturing | In-house Manufacturing | Contract Manufacturing |
| Use | Human, Veterinary | Human | Veterinary |
Competitive Landscape and Market Positioning
Leading companies in the ursodeoxycholic acid market:
- Merck KGaA (Germany)
- Daewoong Bio (South Korea)
- Dipharma Francis S.r.l. (Italy)
- IOL Chemicals and Pharmaceuticals Ltd. (India)
- Glenmark Pharmaceuticals Ltd. (India)
- Axplora (France)
- Anant Pharmaceuticals Pvt Ltd (India)
- ChemChina Pharmaceutical (China)
- Shandong Xinhua Pharmaceutical Co., Ltd. (China)
- Zhongshan Belling Biotechnology Co., Ltd. (China)
Manufacturing excellence has become a defining competitive factor in the ursodeoxycholic acid market as suppliers seek to distinguish themselves through consistent product quality, secure sourcing strategies, and the ability to satisfy increasingly rigorous pharmaceutical standards. Competition is gradually extending beyond bulk production toward specialized capabilities that support differentiated dosage forms, reliable global distribution, and long-term supply commitments for healthcare providers. As regulatory expectations continue to evolve across major pharmaceutical markets, companies with stronger quality assurance systems and flexible manufacturing capabilities are better positioned to capture opportunities in both established and emerging therapeutic applications.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Merck KGaA (Germany) | |||||||
| Daewoong Bio (South Korea) | |||||||
| Dipharma Francis S.r.l. (Italy) | |||||||
| IOL Chemicals and Pharmaceuticals Ltd. (India) | |||||||
| Glenmark Pharmaceuticals Ltd. (India) | |||||||
| Axplora (France) | |||||||
| Anant Pharmaceuticals Pvt Ltd (India) | |||||||
| ChemChina Pharmaceutical (China) | |||||||
| Shandong Xinhua Pharmaceutical Co. Ltd. (China) | |||||||
| Zhongshan Belling Biotechnology Co. Ltd. (China) |
Industry Development / News
| Company Name | Date | Key Development |
|---|---|---|
| Axplora | Jun-26 | Axplora is consolidating its global ursodeoxycholic acid (UDCA) manufacturing at its Vizag, India facility, transitioning production away from its Gropello Cairoli, Italy site by the end of 2026. This move leverages the company’s enzymatic synthesis technology and integrated API platform to enhance supply chain resilience, streamline operations, and increase scalable capacity to meet growing global demand for liver and gallbladder disease therapies. |
| Shilpa Medicare | Aug-25 | Shilpa Medicare received approval from the Central Drugs Standard Control Organization (CDSCO) for its Norursodeoxycholic Acid (NorUDCA) 500 mg tablets to treat Non-Alcoholic Fatty Liver Disease (NAFLD) in India. This novel, bile acid-based therapy addresses a significant unmet medical need and marks a strategic expansion of the company’s hepatology portfolio, following successful Phase 3 clinical trial results demonstrating improved liver function and fibrosis regression. |
| Gilead Sciences | Jan-25 | Gilead Sciences received MHRA approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis in adults. Indicated as an adjunct to ursodeoxycholic acid (UDCA) for patients with inadequate response, or as monotherapy for those unable to tolerate UDCA, the drug—acquired via CymaBay Therapeutics—significantly strengthens Gilead’s competitive position in the liver disease segment by offering a new class of therapy. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Ursodeoxycholic Acid Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Dosage Form | Tablets, Capsules, Oral Solutions & Suspensions |
| Market Positioning | Branded Products, Generic Products |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies |
Ursodeoxycholic Acid Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Indication-Based Demand Assessment |
|
| API Supply & Sourcing Resilience |
|
| Prescriber Adoption Drivers |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How large is the ursodeoxycholic acid market?
How is the ursodeoxycholic acid industry projected to perform over the next decade?
What factors are driving demand for ursodeoxycholic acid therapies?
How is hepatology research supporting growth in the ursodeoxycholic acid market?
Why is in-house manufacturing the leading mode segment in the ursodeoxycholic acid market?
Why is contract manufacturing the fastest-growing mode segment?
Why does North America lead the ursodeoxycholic acid market?
How is Asia Pacific driving future market growth?
Who holds a significant market share in the ursodeoxycholic acid landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook